Short Interest in SciSparc Ltd. (NASDAQ:SPRC) Drops By 56.2%

SciSparc Ltd. (NASDAQ:SPRC) saw a significant decline in short interest in the month of January. As of January 30th, there was short interest totaling 176,031 shares, a decline of 56.2% from the January 15th total of 401,983 shares. Based on an average trading volume of 562,920 shares, the short-interest ratio is currently 0.3 days. Currently, 5.0% of the shares of the company are short sold. Currently, 5.0% of the shares of the company are short sold. Based on an average trading volume of 562,920 shares, the short-interest ratio is currently 0.3 days.

SciSparc Stock Performance

SPRC opened at $0.60 on Friday. The business has a fifty day simple moving average of $1.24 and a 200 day simple moving average of $2.86. SciSparc has a 1 year low of $0.58 and a 1 year high of $11.51.

SciSparc (NASDAQ:SPRC) last announced its earnings results on Tuesday, November 18th. The company reported ($3.08) earnings per share (EPS) for the quarter. The firm had revenue of $0.23 million for the quarter.

About SciSparc

SciSparc AG is a clinical‐stage medical technology company focused on the development and commercialization of extracorporeal shock wave–based neuromodulation devices. Founded in 2016 and headquartered in Switzerland, the company applies proprietary low‐intensity shock wave technology to noninvasively stimulate neural tissue. SciSparc completed its initial public offering on the NASDAQ in 2021 under the ticker SPRC, securing funding to advance its clinical pipeline.

The company’s lead product, the TR100 system, delivers transcranial shock wave stimulation (tSWS) designed to target areas of the brain associated with motor control and cognitive function.